VITEK 2 AST-Streptococcus Meropenem (=0.06 - =4 µg/mL)
BIOMERIEUX, Inc. · Decision date Oct 1, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-01 for K260283, submitted by bioMerieux, Inc. of Hazelwood, Missouri. The device is listed as VITEK 2 AST-Streptococcus Meropenem (=0.06 - =4 µg/mL), an automated short-incubation antimicrobial susceptibility test system under regulation 866.1645, product code LON, in the microbiology specialty. The application was received 01/29/2026 and reviewed as a traditional 510(k) by FDA rather than a third party.
SESE in this 510(k) context denotes clearance of the submission, not premarket approval of a new device. The record states that a Predetermined Change Control Plan was authorized and that the submission was not a combination product. The public record does not include the decision summary text, performance data, or the specific modifications described in the authorized change control plan, so the scope of what was cleared beyond the listed device name and range cannot be determined from this source.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Oct 1, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260283
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- BIOMERIEUX, Inc.
- Product code
- LON
- Decision code
- SESE
- Decision date
- Oct 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Test, Automated, Antimicrobial Susceptibility, Short Incubation.
- Applicant
- BIOMERIEUX, Inc.
- Product code
- LON
- FDA device class
- 2
FDA decision timeline
K260283 received
Application receipt date recorded by FDA.
K260283 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code LON
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| BIOMERIEUX, Inc. | 510(k) clearance | Nov 4, 2026 | FDA | |
VITEK PROK262683 | bioMérieux, Inc. | 510(k) clearance | Nov 3, 2026 | FDA |
| bioMérieux, Inc. | 510(k) clearance | Sep 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
BIOMERIEUX, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Hazelwood, MO
Sources and methodology
- Original FDA record: K260283
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

